Grafalon

Grafalon is a rabbit-derived anti‑T‑lymphocyte immunoglobulin formulated as a solution for injection. It contains the active ingredient anti‑T lymphocyte immunoglobulin for human use, supplied in a strength that is not specified in the public label. Grafalon is administered intravenously under prescription and is classified as an immunosuppressant used primarily in organ transplantation and graft‑versus‑host disease management. It is marketed in the European Union and follows EU regulatory standards.

Grafalon is indicated for specific immunological conditions where suppression of T‑cell activity is required.

- Prevention of acute rejection in solid‑organ transplantation (e.g., kidney, liver, heart). - Treatment and prophylaxis of graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation. - Induction therapy in high‑risk transplant recipients to reduce early immune activation. - Adjunctive immunosuppression in combined‑organ transplant protocols. - Use in desensitization protocols for sensitized patients awaiting transplantation. - Support in experimental protocols for autoimmune disease modulation under clinical investigation.

The immunological activity of Grafalon can be associated with a range of adverse events, which are generally categorized by frequency and severity.

Common: - Fever, chills, or rigors during or shortly after infusion. - Transient hypertension or hypotension. - Nausea, vomiting, or mild gastrointestinal discomfort. - Headache or dizziness. - Mild rash or urticaria. - Elevated liver enzymes.

Serious: - Severe infusion‑related reactions such as anaphylaxis or bronchospasm. - Cytokine release syndrome presenting with high fever and organ dysfunction. - Opportunistic infections due to profound T‑cell depletion (e.g., CMV, fungal infections).

Because Grafalon produces marked immunosuppression, careful patient assessment and monitoring are required before and during therapy.

- Verify negative screening for active infections (e.g., hepatitis B/C, HIV, tuberculosis) prior to initiation. - Assess baseline cardiac function; monitor blood pressure and heart rate during infusion. - Perform complete blood count and differential to detect early leukopenia or thrombocytopenia. - Evaluate renal and hepatic function; dose adjustments may be needed in impairment. - Counsel patients on infection‑prevention measures and the need to report fever or respiratory symptoms promptly. - Consider pregnancy risk; avoid use in pregnant women unless benefits outweigh unknown risks.

Grafalon may interact with other agents that affect immune function or complement activity, requiring dose adjustments or heightened monitoring.

Avoid: - Concurrent use of other potent immunosuppressants (e.g., high‑dose corticosteroids, calcineurin inhibitors) without close therapeutic drug monitoring. - Live vaccines administered during or shortly after treatment, due to risk of uncontrolled infection. - Complement‑inhibiting drugs that could alter Grafalon’s mechanism of action.

Use with caution: - Antithymocyte globulin preparations from other species, as additive immunosuppression may increase infection risk. - Cytotoxic chemotherapy agents, which may exacerbate bone‑marrow suppression. - Antiviral prophylaxis agents (e.g., ganciclovir) that require renal dosing adjustments when combined with Grafalon.